August 21, 2020
1 min read
Save
LensGen closes $10 million financing, adds Jim Mazzo to board
LensGen has closed on $10 million to help fund the Juvene IOL pivotal FDA study, according to a press release.
This initial funding is part of a larger Series B financing planned for 2021.
Juvene, a disruptive fluid-optic IOL, is under development for the treatment of cataract and presbyopia.
James V. Mazzo
In addition, James V. Mazzo has been elected to the company’s board of directors.
“LensGen has a unique platform technology that I believe represents the future of cataract and lens replacement surgery,” Mazzo said in the release.
Published by:
Read more about